leukaemia – HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

The FDA has approved Pfizer’s Besponsa drug for pediatric patients aged one year and above to treat acute leukaemia.

Drugs Health Pharma

Pfizer’s pediatric leukaemia drug gets regulator FDA’s green light

HQ Team March 7, 2024: The FDA has approved Pfizer’s Besponsa drug for pediatric patients aged one year and above to treat acute.

by HealthQuill
March 7, 2024
0 Comments

Read More

India’s Immunoactive Cell Therapy Ltd., has got a marketing authorisation from the drug regulator for a therapy to treat leukaemia and cancer of the lymphatic system.

Drugs Health Pharma

ImmunoACT gets nod for leukaemia, lymphoma cancer therapy in India

HQ Team October 16, 2023: India’s Immunoactive Cell Therapy Ltd., has got a marketing authorisation from the drug regulator for a therapy to.

by HealthQuill
October 16, 2023
0 Comments

Read More

Breast cancer

Drugs Health Medical

Leukaemia drug effective in treating breast cancer metastatic relapse

A mice study showed promising results in treating secondary recurrence of breast cancer in lungs

by HealthQuill
March 14, 2023
0 Comments

Read More